靶点- |
作用机制- |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2008-10-16 |
A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.
100 项与 天津睿瀛生物科技有限公司 相关的临床结果
0 项与 天津睿瀛生物科技有限公司 相关的专利(医药)
100 项与 天津睿瀛生物科技有限公司 相关的药物交易
100 项与 天津睿瀛生物科技有限公司 相关的转化医学